Acute Migraine Treatment: Evidence-Based Approach
Start with an NSAID (ibuprofen, naproxen sodium, diclofenac potassium, or aspirin) at adequate dosing, and if this fails to provide sufficient pain relief, immediately escalate to combination therapy with a triptan plus an NSAID (or acetaminophen if NSAIDs are contraindicated). 1
Treatment Algorithm
Step 1: Initial Assessment and First-Line Treatment
Begin with NSAIDs as monotherapy for moderate to severe migraine:
- Ibuprofen, naproxen sodium, diclofenac potassium, or aspirin
- Critical point: Ensure adequate dosing—many patients fail on NSAIDs simply because they're taking subtherapeutic doses 1
- Acetaminophen is an alternative but less effective than NSAIDs 1
Timing matters: Counsel patients to treat as early as possible after attack onset to maximize efficacy 1
Step 2: Escalation to Combination Therapy
If NSAIDs at adequate doses fail, add a triptan to the NSAID (or to acetaminophen if NSAIDs contraindicated):
- This combination provides superior outcomes compared to either agent alone 1
- High-certainty evidence shows combination therapy (triptan + NSAID) results in:
- 180 more people per 1000 achieving sustained pain relief up to 48 hours
- 160 fewer people per 1000 needing rescue medication 1
Specific triptan selection (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, or zolmitriptan) should be based on route preference and cost, as patients may respond differently to different triptans within the class 1
Step 3: Third-Line Options
For patients who fail combination therapy or have contraindications to triptans:
- CGRP antagonists (gepants): rimegepant, ubrogepant, or zavegepant 1
- Dihydroergotamine 1
- These have supporting efficacy data but uncertain comparative effectiveness 1
Step 4: Fourth-Line Treatment
Lasmiditan (ditan) is reserved for patients who fail all other treatments in this guideline 1
- Note: Causes driving impairment; patients cannot operate machinery for at least 8 hours after intake 2
Special Considerations
Severe Nausea/Vomiting
Use nonoral triptan formulations (nasal spray, subcutaneous injection) plus prokinetic antiemetics (domperidone or metoclopramide) 1, 2
Pregnancy and Lactation
- Acetaminophen is the safest option 3
- Sumatriptan may be considered in selected patients and is compatible with breastfeeding 3
- Discuss adverse effects of all pharmacologic treatments with patients of childbearing potential 1
Critical Pitfalls to Avoid
Medication Overuse Headache (MOH)
- Defined as headache ≥15 days/month for ≥3 months due to acute medication overuse 1
- Thresholds vary by medication (e.g., ≥15 days/month for NSAIDs/acetaminophen; ≥10 days/month for triptans) 1
- If frequent episodic migraine or inadequate response persists, add preventive medications rather than increasing acute medication frequency 1
Medications to Absolutely Avoid
Do not use opioids or butalbital for acute episodic migraine 1
- Questionable efficacy, considerable adverse effects, and dependency risk 2
- Oral ergot alkaloids are poorly effective and potentially toxic—avoid as triptan substitutes 2
Cost Considerations
The 2025 ACP guideline explicitly considered costs 1:
- NSAIDs, acetaminophen, triptans, and their combinations: ~$500 annualized
- CGRP antagonists (gepants): $5,994 annualized
- Lasmiditan: $6,668 annualized
This cost differential, combined with high-certainty efficacy data for NSAIDs and triptans, strongly supports the stepwise approach outlined above.
Strength of Evidence
The 2025 American College of Physicians guideline 1 represents the highest quality and most recent evidence available, with high-certainty evidence for triptan + NSAID combinations and moderate-to-high certainty evidence for individual agents. This guideline supersedes older recommendations and should guide current practice.